Literature DB >> 23597587

Clostridium difficile PSI polysaccharide: synthesis of pentasaccharide repeating block, conjugation to exotoxin B subunit, and detection of natural anti-PSI IgG antibodies in horse serum.

Yuening Jiao1, Zuchao Ma, Doug Hodgins, Brittany Pequegnat, Lisa Bertolo, Luis Arroyo, Mario A Monteiro.   

Abstract

Clostridium difficile is the most common cause of antimicrobial-associated diarrhea in humans and may cause death. Previously, we discovered that C. difficile expresses three polysaccharides, named PSI, PSII, and PSIII. It has now been established that PSII is a conserved antigen abundantly present on the cell-surface and biofilm of C. difficile. In contrast, the expression of PSI and PSIII appears to be stochastic processes. In this work, the total chemical synthesis of the PSI pentasaccharide repeating unit carrying a linker at the reducing end, α-l-Rhap-(1→3)-β-d-Glcp-(1→4)-[α-l-Rhap-(1→3)]-α-d-Glcp-(1→2)-α-d-Glcp-(1→O(CH2)5NH2, was achieved by a linear synthesis strategy from four monosaccharide building blocks. The synthesized PSI pentasaccharide was conjugated to a subunit of C. difficile exotoxin B yielding a potential dual C. difficile vaccine. More significantly, sera from healthy horses were shown to contain natural anti-PSI IgG antibodies that detected both the synthetic non-phosphorylated PSI repeat and the native PSI polysaccharide, with a slightly higher recognition of the native PSI polysaccharide.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-PSI IgG antibodies; C. difficile PSI polysaccharide; C. difficile Toxin B conjugate; Clostridium difficile; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 23597587     DOI: 10.1016/j.carres.2013.03.018

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  8 in total

Review 1.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

Review 2.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

3.  Overview of Clostridium difficile infection: implications for China.

Authors:  Xinhua Chen; J Thomas Lamont
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-11-04

Review 4.  Carbohydrate Scaffolds for the Study of the Autism-associated Bacterium, Clostridium bolteae.

Authors:  Brittany Pequegnat; Mario A Monteiro
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

5.  Synthetic Oligosaccharide-Based Vaccines Protect Mice from Clostridioides difficile Infections.

Authors:  Felix Broecker; Erik Wegner; Bruna M S Seco; Paulina Kaplonek; Maria Bräutigam; Armin Ensser; Frederick Pfister; Christoph Daniel; Christopher E Martin; Jochen Mattner; Peter H Seeberger
Journal:  ACS Chem Biol       Date:  2019-11-19       Impact factor: 5.100

6.  Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.

Authors:  Yunqin Zhang; Yanlei Hu; Shanshan Liu; Haiqing He; Roujing Sun; Gang Lu; Guozhi Xiao
Journal:  Chem Sci       Date:  2022-05-27       Impact factor: 9.969

7.  Multivalent display of minimal Clostridium difficile glycan epitopes mimics antigenic properties of larger glycans.

Authors:  Felix Broecker; Jonas Hanske; Christopher E Martin; Ju Yuel Baek; Annette Wahlbrink; Felix Wojcik; Laura Hartmann; Christoph Rademacher; Chakkumkal Anish; Peter H Seeberger
Journal:  Nat Commun       Date:  2016-04-19       Impact factor: 14.919

Review 8.  Characteristics of the Clostridium difficile cell envelope and its importance in therapeutics.

Authors:  Joseph A Kirk; Oishik Banerji; Robert P Fagan
Journal:  Microb Biotechnol       Date:  2016-06-17       Impact factor: 5.813

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.